AtriCure, Inc. filings document financial results, governance matters and capital arrangements for a Nasdaq-listed medical technology company focused on Afib, left atrial appendage management and post-operative pain management. Form 8-K reports furnish quarterly and annual results, amended financial guidance disclosures, product-revenue drivers and material definitive agreements, including an asset-based revolving credit facility involving AtriCure, LLC as a borrower.
Proxy filings cover board and shareholder voting matters, executive compensation, equity awards and related governance disclosures. The filings also identify AtriCure common stock as registered on the Nasdaq Global Market under the symbol ATRC.
AtriCure, Inc. filed a notice of proposed sale of common stock under Rule 144. The filing lists a planned sale of 6,182 shares of common stock through RBC Capital Markets LLC on the NASDAQ market, associated with an aggregate value of $239,882.00. The shares to be sold were acquired via stock grants of 2,712 shares on March 1, 2023 and 3,470 shares on March 1, 2024.
Vinayak Doraiswamy, a shareholder of AtriCure, Inc. (symbol ATRC), has filed to sell 6,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists an aggregate market value of $233,278.80 for these shares, with AtriCure common shares outstanding reported at 50,866,294. The proposed sale date is July 28, 2026.
The shares to be sold relate to performance share awards dated March 1, 2023 (2,596 shares) and March 1, 2025 (3,404 shares). In the past three months, a prior sale of 5,000 common shares on May 15, 2026 for proceeds of $140,674.00 is also reported.
AtriCure, Inc. reported strong second quarter 2026 results, with worldwide revenue of $153.6 million, up 12.8% year over year (12.4% on a constant currency basis). U.S. revenue grew to $125.6 million, driven by cryoSPHERE MAX pain management probes, EnCompass clamps, and AtriClip FLEX-Mini and PRO-Mini devices; international revenue rose to $28.0 million.
Gross profit increased to $118.6 million and gross margin expanded to 77.2%, supported by favorable product and geographic mix and manufacturing efficiencies. The company generated income from operations of $9.7 million versus an operating loss a year earlier and net income of $9.0 million, or $0.18 per basic and diluted share, compared with a net loss of $6.2 million, or $0.13 per share, in second quarter 2025.
Adjusted EBITDA reached $27.3 million, up $11.9 million or 78% from the prior-year quarter, and cash generation was $21.6 million. For full year 2026, management projects revenue of $602 million to $610 million, adjusted EBITDA of $85 million to $89 million, net income per share of $0.05 to $0.13, and adjusted earnings per share of $0.24 to $0.32, with continued positive cash generation.
AtriCure, Inc. President and CEO Michael H. Carrel reported a new share acquisition through an employee purchase program. On June 30, 2026, he acquired 636 shares of common stock directly at an effective price of $23.78 per share under AtriCure’s 2018 Employee Stock Purchase Plan.
These shares were purchased at 85% of the $27.98 closing price on June 30, 2026, as provided by the plan. After this transaction, Carrel directly holds 779,134 common shares. Additional indirect holdings are reported as shares held by his sibling, parents, and children, for which he disclaims beneficial ownership except for any pecuniary interest.
Chief Scientific Officer Doraiswamy Vinayak acquired additional AtriCure, Inc. common stock through an employee purchase program. On June 30, 2026, he obtained 636 shares of Common Stock pursuant to the company’s 2018 Employee Stock Purchase Plan at $23.78 per share, a price based on 85% of the $27.98 closing price that day. Following this transaction, he directly holds 92,511 common shares, reflecting a small, routine compensation-related acquisition rather than an open-market trade.
AtriCure, Inc. reported that Chief Legal Officer Karl S. Dahlquist acquired 636 shares of common stock on June 30, 2026 through the company’s 2018 Employee Stock Purchase Plan. The shares were acquired at approximately $23.78 per share, based on 85% of the $27.98 closing price on that date, bringing his direct holdings to 96,689 shares.
AtriCure, Inc. Chief Operating Officer Douglas J. Seith acquired 527 shares of common stock through the company’s 2018 Employee Stock Purchase Plan for the period ended June 30, 2026. The shares were purchased at $23.78 each, bringing his direct holdings to 229,867 shares.
AtriCure, Inc. Chief Technical Officer Salvatore Privitera acquired additional company stock through an employee plan. On June 30, 2026, he received 636 shares of common stock, bringing his direct holdings to 158,684 shares. The shares were bought under AtriCure's 2018 Employee Stock Purchase Plan for the period ended June 30, 2026.
According to the plan terms, these shares were purchased at 85% of the June 30, 2026 closing price of $27.98 per share, resulting in an effective purchase price of $23.78 per share. This is a routine compensation-related acquisition rather than an open-market trade.